Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (223) Apply Press releases filter
- Basic page (55) Apply Basic page filter
- Corporate presentations (24) Apply Corporate presentations filter
- Pipeline (24) Apply Pipeline filter
- Shareholder meeting (21) Apply Shareholder meeting filter
- Team member (20) Apply Team member filter
- Videos (15) Apply Videos filter
- Financial reports (12) Apply Financial reports filter
- Analyst (11) Apply Analyst filter
- Webcasts and audio (11) Apply Webcasts and audio filter
- Event (7) Apply Event filter
- Investor contact (6) Apply Investor contact filter
- Research (3) Apply Research filter
Oxford BioMedica Presents Ground-Breaking Evidence of Long-Term Duration of Therapeutic Expression in Patients from its Proprietary LentiVector® Gene Delivery Platform
Oxford, UK – 6 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy com
Oxford BioMedica Preliminary Results Replay
Encore is InterCall's recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or w
Oxford BioMedica Announces Stuart Henderson Appointed as a Non-Executive Director
London, UK – 26 April 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica Announces Expanded Collaboration and Licence with Immune Design
Oxford, UK – 7 March 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy gr
Oxford BioMedica announces a proposed placing to raise £8.1 Million
Oxford, UK – 23 February 2016: Oxford BioMedica plc (“Oxford BioMedica” or the “Company”, together with its subsidiaries, the “Gro
Oxford BioMedica Announces Initiation of Second CART Programme for Major Pharmaceutical Company
Oxford, UK – 29 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy
Board change
Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016.
From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT).